Usefulness of Alpha-GST in Liver Transplantation
GST-LT
Predictive Ability of Alpha-GST to Detect Graft Primary Dysfunction After Liver Transplantation
1 other identifier
observational
100
1 country
1
Brief Summary
The primary objective of this study was to evaluate the ability of plasma alpha-GST measurements in liver donor (at the time of organ removal) to predict primary dysfunction in liver recipient. The secondary objective was to study the relationship between alpha-GST levels in the plasma of the liver transplant recipient and early graft function recovery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 19, 2015
CompletedFirst Posted
Study publicly available on registry
May 21, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2015
CompletedMay 21, 2015
May 1, 2015
1.6 years
May 19, 2015
May 20, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Primary dysfunction (PDF) of liver graft
To evaluate the ability of plasma alpha-GST measurements in liver donor (at the time of organ removal) to PDF in liver recipient.
First week
Secondary Outcomes (1)
Early graft function recovery.
First week
Eligibility Criteria
Patients undergoing liver transplantation at Beaujon hospital (APHP, Clichy, France)
You may qualify if:
- age \> 18 years
- undergoing liver transplantation at Beaujon hospital (APHP, Clichy, France )
You may not qualify if:
- age \>70 years and \<18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Beaujon Hospitallead
Study Sites (1)
Réanimation hépato-digestive
Clichy, F-92210, France
Study Officials
- PRINCIPAL INVESTIGATOR
Catherine Paugam-Burtz, MD-PhD
Assistance Publique - Hôpitaux de Paris
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 7 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 19, 2015
First Posted
May 21, 2015
Study Start
March 1, 2014
Primary Completion
October 1, 2015
Study Completion
October 1, 2015
Last Updated
May 21, 2015
Record last verified: 2015-05